Monoclonal antibodies targeting IL-17, such as secukinumab and ixekizumab, are commonly used in the treatment of rheumatic diseases and are being evaluated for their potential in strategies targeting IL-17 in psoriasis associated with NASH. Here, IL17A is linked to rheumatic disorder.